Nifty Pharma Index Rises 0.3% as Zydus Life, Dr Reddys Lab, Ajanta Pharma Lead Gainers

The Nifty Pharma index rose 0.3 percent in intraday trade on Wednesday, 8 July 2026, standing out as one of the few sectors in the green even as the broader market traded weak on global cues. Zydus Life, Dr Reddy’s Lab and Ajanta Pharma were among the top contributors to the index gain.

Zydus Life led the pharma pack with a 1.14 percent gain to Rs 1,166.20, followed by Dr Reddy’s Labs which rose 0.9 percent to Rs 1,366.80, as the Nifty Pharma index attracted buying interest amid the broader selloff.

Click Here – Get Free Investment Predictions

Nifty Pharma Top Stock Gainers Today

Company	CMP	Chg(%)	Volume
Zydus Life	Rs 1,166.20	+1.14 percent	722.49k
Dr Reddys Labs	Rs 1,366.80	+0.90 percent	448.14k
Ajanta Pharma	Rs 3,341.60	+0.82 percent	29.23k
Torrent Pharma	Rs 4,896.30	+0.82 percent	53.34k
JB Chemicals	Rs 2,437.00	+0.62 percent	91.40k
Cipla	Rs 1,459.30	+0.52 percent	212.14k
Lupin	Rs 2,502.90	+0.51 percent	194.88k
Aurobindo Pharm	Rs 1,590.60	+0.47 percent	182.06k
Sun Pharma	Rs 1,910.90	+0.39 percent	571.33k
Alkem Lab	Rs 5,686.00	+0.33 percent	17.12k
Divis Labs	Rs 6,788.50	+0.25 percent	38.76k
Wockhardt	Rs 1,860.00	+0.14 percent	120.25k

Get Pharma Sector Guidance from a SEBI Registered Investment Advisor at Univest

Why the Nifty Pharma Index Is Outperforming Today

Pharma stocks are traditionally viewed as a defensive sector during periods of macro uncertainty, since demand for medicines is relatively inelastic regardless of oil prices, currency moves or geopolitical tensions. With crude oil rallying on renewed US Iran conflict and rate sensitive sectors such as banking and aviation under pressure, investors appear to have rotated some capital into pharma names.

The breadth of gains across the Nifty Pharma index, spanning large caps like Sun Pharma and Cipla to mid sized names like JB Chemicals and Ajanta Pharma, suggests broad based buying rather than a single stock specific trigger.

What Should Investors Watch in the Nifty Pharma Index

Investors tracking the Nifty Pharma index should watch Q1 FY27 earnings commentary on US generics pricing, domestic formulation growth and R&D pipeline updates. Currency movements also matter given the sector’s significant export revenue exposure to the US market.

Download the Univest iOS App or Univest Android App to track pharma stocks live and get daily research updates.

Conclusion

The Nifty Pharma index rose 0.3 percent on 8 July 2026, led by Zydus Life, Dr Reddy’s Lab and Ajanta Pharma, as defensive pharma names outperformed a weak broader market hurt by rising crude oil prices. Investors should track Q1 FY27 earnings and export trends, and consult a SEBI registered advisor before investing in pharma stocks.

Frequently Asked Questions FAQs

Why did the Nifty Pharma index rise today?

Ans. The Nifty Pharma index rose 0.3 percent on 8 July 2026 as investors rotated into defensive pharma stocks while the broader market fell on rising crude oil prices and global tensions.

How many stocks make up the Nifty Pharma index?

Ans. The Nifty Pharma index tracks a basket of major listed pharmaceutical companies, including Zydus Life, Dr Reddys Labs, Sun Pharma, Cipla, Lupin and Divis Labs among its key constituents.

Which pharma stock gained the most today?

Ans. Zydus Life was the top gainer on the Nifty Pharma index, rising 1.14 percent to Rs 1,166.20 on 8 July 2026.

What is the Dr Reddy’s Labs share price today?

Ans. Dr Reddy’s Labs share price was trading at Rs 1,366.80 on 8 July 2026, up 0.9 percent, making it one of the top contributors to the Nifty Pharma index gain.

Why is pharma considered a defensive sector?

Ans. Pharma is considered defensive because demand for medicines remains relatively stable regardless of macroeconomic or geopolitical conditions, unlike oil sensitive or rate sensitive sectors.

Which other pharma stocks gained today?

Ans. Ajanta Pharma, Torrent Pharma, JB Chemicals, Cipla, Lupin, Aurobindo Pharma, Sun Pharma, Alkem Lab, Divis Labs and Wockhardt all posted gains between 0.14 and 0.82 percent on 8 July 2026.

Should investors buy pharma stocks after today’s gains?

Ans. A single day of outperformance is not a standalone buy signal. Investors should review Q1 FY27 earnings, US generics pricing trends and valuations, and consult a SEBI registered investment advisor before investing.